LF 18-1505T(LF 18-1505T) - 药物靶点：B2 receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名

LF 18-1505T

靶点

B2 receptor

作用方式

拮抗剂

作用机制

B2 receptor拮抗剂(缓激肽B2受体拮抗剂)

治疗领域

神经系统疾病其他疾病

在研适应症-

非在研适应症

颅脑损伤

原研机构

Fournier Pharma SA

在研机构-

非在研机构

Ben-Gurion University of the Negev

权益机构-

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 LF 18-1505T 相关的临床结果

登录后查看更多信息

100 项与 LF 18-1505T 相关的转化医学

登录后查看更多信息

100 项与 LF 18-1505T 相关的专利（医药）

登录后查看更多信息

1

项与 LF 18-1505T 相关的文献（医药）

2006-10-01·The Journal of trauma

Bradykinin B2 Receptor Antagonism With LF 18-1505T Reduces Brain Edema and Improves Neurological Outcome After Closed Head Trauma in Rats

Article

作者: Yoram Shapira ; Alan A. Artru ; Mony Benifla ; Albert Svetnitsky ; Yulia Fuxman ; Olga Mayzler ; Avi Cohen ; Yulia Ivashkova ; Didier Pruneau

BACKGROUND:

We evaluated the effect of LF 18-1505T, a novel nonpeptide bradykinin type-2 receptor antagonist, on brain edema and neurologic severity score (NSS) after closed head trauma (CHT).

METHODS:

There were 132 rats anesthetized and assigned for sham or CHT; infusion of saline or LF 18-1505T (0.3, 1, 3, 10, or 30 microg x kg x min); and determination of neurologic outcome (brain water content and NSS) or physiologic variables (blood pressure, glucose concentration, etc.).

RESULTS:

Post-CHT brain water content was less with LF 18-1505T doses of 3 and 10 microg x kg x min (80.1 +/- 3.8 through 81.6 +/- 2.6%, mean +/- SD) than in the untreated group (84.6 +/- 1.9%, p < 0.01). Post-CHT NSS improved with doses of 3, 10, and 30 microg x kg x min (median, 7; range, 0-12 through median, 10; range, 8-18) as compared with that in the untreated group (median, 17; range, 14-23; p < 0.05). LF 18-1505T with or without CHT did not significantly alter physiologic variables.

CONCLUSIONS:

LF 18-1505T decreased brain edema and improved neurologic status after CTH in rats without significantly altering physiologic values.

100 项与 LF 18-1505T 相关的药物交易

登录后查看更多信息